Menu
Search
|

Menu

Close
X

Collegium Pharmaceutical Inc COLL.OQ (NASDAQ Stock Exchange Global Select Market)

20.15 USD
+0.13 (+0.65%)
As of 1:30 AM IST
chart
Previous Close 20.02
Open 19.95
Volume 156,815
3m Avg Volume 163,616
Today’s High 20.63
Today’s Low 19.81
52 Week High 29.80
52 Week Low 9.03
Shares Outstanding (mil) 29.57
Market Capitalization (mil) 348.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
64
FY17
28
FY16
2
FY15
0
EPS (USD)
FY18
-0.567
FY17
-2.485
FY16
-3.870
FY15
-2.751
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
46.84
5.73
Price to Book (MRQ)
vs sector
3.65
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
2.96
16.84
LT Debt to Equity (MRQ)
vs sector
0.46
12.51
Return on Investment (TTM)
vs sector
-99.46
14.61
Return on Equity (TTM)
vs sector
-101.15
16.34

EXECUTIVE LEADERSHIP

Michael Heffernan
Chairman of the Board, President, Since 2018
Salary: $380,380.00
Bonus: --
Joseph Ciaffoni
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Paul Brannelly
Chief Financial Officer, Executive Vice President, Since 2015
Salary: --
Bonus: --
Shirley Kuhlmann
Executive Vice President, General Counsel, Secretary, Since 2018
Salary: --
Bonus: --
Douglas Carlson
Vice President - Corporate Development, Since 2013
Salary: $231,750.00
Bonus: $15,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

780 Dedham St Ste 800
CANTON   MA   02021-1417

Phone: +1781.7133699

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

SPONSORED STORIES